HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Josef S Smolen Selected Research

Rheumatoid Arthritis

11/2015	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs.
8/2015	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
6/2015	Clocking in: chronobiology in rheumatoid arthritis.
1/2015	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.
1/2015	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
1/2015	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
1/2015	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.
1/2015	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
1/2015	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
10/2014	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research network!

Josef S Smolen Research Topics

Disease

93	Rheumatoid Arthritis 11/2015 - 03/2002
28	Arthritis (Polyarthritis) 01/2015 - 01/2002
20	Inflammation 01/2015 - 03/2002
16	Necrosis 09/2015 - 04/2003
13	Rheumatic Diseases (Rheumatism) 06/2015 - 01/2007
11	Systemic Lupus Erythematosus (Libman-Sacks Disease) 02/2015 - 03/2002
10	Pain (Aches) 01/2016 - 11/2002
7	Psoriatic Arthritis 11/2012 - 07/2002
6	Infection 02/2015 - 11/2004
6	Bone Resorption 01/2010 - 07/2002
5	Ankylosing Spondylitis 04/2013 - 07/2002
4	Osteoarthritis 11/2014 - 07/2004
4	Autoimmune Diseases (Autoimmune Disease) 05/2008 - 03/2002
3	Joint Diseases (Joint Disease) 01/2014 - 04/2003
3	Lupus Nephritis 03/2012 - 05/2008
3	Mixed Connective Tissue Disease (MCTD) 07/2011 - 08/2005
3	Systemic Scleroderma (Systemic Sclerosis) 05/2008 - 08/2005
2	Fatigue 01/2016 - 03/2012
2	Synovitis 04/2014 - 05/2009
2	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 04/2013 - 04/2013
2	Pneumonia (Pneumonitis) 03/2012 - 11/2004
2	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2012 - 11/2009
2	Acute-Phase Reaction 09/2010 - 07/2002
2	Osteoporosis 04/2009 - 07/2004
2	Nephritis 07/2008 - 10/2004
2	Vascular Diseases (Vascular Disease) 12/2005 - 08/2005
1	Arthralgia (Joint Pain) 06/2015
1	Dermatitis 01/2015
1	Glomerulonephritis 01/2015
1	Cadaver (Cadavers) 11/2014
1	Edema 04/2014

Drug/Important Bio-Agent (IBA)

30	Methotrexate (Mexate)FDA LinkGeneric 08/2015 - 10/2004
27	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 03/2002
17	infliximab (Remicade)FDA Link 03/2014 - 10/2004
16	Antirheumatic Agents (DMARD)IBA 11/2015 - 04/2002
12	AutoantibodiesIBA 01/2015 - 01/2003
10	adalimumab (Humira)FDA Link 01/2015 - 04/2003
9	C-Reactive ProteinIBA 04/2014 - 07/2002
9	tocilizumab FDA Link 03/2014 - 12/2007
8	AntibodiesIBA 01/2015 - 08/2005
8	leflunomide (Arava)FDA LinkGeneric 01/2014 - 06/2004
7	GlucocorticoidsIBA 09/2015 - 02/2005
6	Interleukin-6 (Interleukin 6)IBA 06/2015 - 03/2008
6	golimumab FDA Link 01/2015 - 07/2009
6	rituximab (Mabthera)FDA Link 03/2014 - 07/2007
5	CDP870 FDA Link 01/2015 - 11/2009
5	TNFR-Fc fusion protein (etanercept)FDA Link 03/2014 - 05/2005
5	CytokinesIBA 01/2011 - 11/2002
4	Prostaglandins A (PGA)IBA 01/2016 - 09/2012
4	CollagenIBA 01/2015 - 07/2002
4	ametantrone (HAQ)IBA 01/2015 - 04/2007
4	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 02/2006
4	abatacept (BELATACEPT)FDA Link 01/2015 - 07/2007
4	Acute-Phase Proteins (Acute-Phase Protein)IBA 04/2013 - 01/2005
4	Biological Markers (Surrogate Marker)IBA 01/2010 - 07/2002
4	OsteoprotegerinIBA 02/2004 - 03/2002
3	Rheumatoid FactorIBA 01/2015 - 11/2002
3	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2014 - 06/2004
3	Interleukin-1 (Interleukin 1)IBA 06/2012 - 12/2003
3	Immunoglobulins (Immunoglobulin)IBA 06/2011 - 12/2007
3	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2006 - 07/2002
2	apremilastIBA 09/2015 - 01/2014
2	Proteins (Proteins, Gene)IBA 01/2015 - 05/2008
2	diazenedicarboxylic acid bis(N'-methylpiperazide)IBA 11/2014 - 04/2013
2	Phosphotransferases (Kinase)IBA 01/2014 - 01/2005
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 04/2013 - 12/2007
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 05/2012 - 06/2010
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 03/2012 - 02/2011
2	Azathioprine (Imuran)FDA LinkGeneric 06/2010 - 10/2004
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2010 - 11/2004
2	OsteocalcinIBA 01/2010 - 01/2006
2	pristane (pristan)IBA 01/2010 - 12/2007
2	AntigensIBA 10/2008 - 05/2008
2	Immunoglobulin G (IgG)IBA 12/2007 - 08/2005
2	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2006 - 01/2003
2	JNK Mitogen-Activated Protein KinasesIBA 01/2005 - 01/2005
2	Indicators and Reagents (Reagents)IBA 11/2003 - 01/2002
2	deoxypyridinolineIBA 07/2003 - 07/2002
2	AutoantigensIBA 07/2002 - 03/2002
1	monoclonal antibody CNTO 1275 (CNTO 1275)FDA Link 09/2015
1	B-Cell Activating FactorIBA 08/2015
1	TESIBA 06/2015
1	HormonesIBA 06/2015
1	Immunosuppressive Agents (Immunosuppressants)IBA 02/2015
1	belimumabIBA 02/2015
1	Anti-Idiotypic AntibodiesIBA 01/2015
1	acetyl 4-aminosalicylic acidIBA 01/2015
1	tensins (tensin)IBA 01/2015
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2015
1	Histones (Histone)IBA 01/2015
1	GoldIBA 01/2014
1	imatinib (Gleevec)FDA Link 01/2014
1	R788 compoundIBA 01/2014

Therapy/Procedure

7	Drug Therapy (Chemotherapy) 04/2013 - 12/2003
4	Therapeutics 01/2014 - 06/2003
3	Aftercare (After-Treatment) 01/2015 - 07/2009
2	Biological Therapy 01/2013 - 06/2011
2	Transplantation (Transplant Recipients) 06/2010 - 12/2005
1	Chronotherapy 06/2015
1	Off-Label Use 02/2015